Host: John J. Russell, MD

Guest: David A. Reardon, MD

Glioblastoma Multiforme (GBM) is the most common and most malignant of all glial tumors. These tumors present a challenge to the team managing the patient, as there is no curative treatment; the goal is to find the best approach and optimal role for each team member. There are a variety of treatment options, which include surgery (resection), radiotherapy, and chemotherapy. The prognosis for these patients is measured in years with respect to median survival; with one study reporting nearly 10% of patients live five years or longer. The current clinical research environment includes a variety of new approaches to treating patients with GBM, and antibody-drug conjugates (ADCs) are one type of treatment currently being investigated. In today's activity we will discuss the role of ADCs in managing patients with GBM.